{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:16:30Z","timestamp":1791832590926,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 EY01583-26"],"award-info":[{"award-number":["P30 EY01583-26"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.oret.2020.03.019","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T03:44:17Z","timestamp":1585799057000},"page":"889-898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy"],"prefix":"10.1016","volume":"4","author":[{"given":"Benjamin J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gehrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert O.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-2801","authenticated-orcid":false,"given":"Yafeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul N.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzhak","family":"Nissim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5973-6616","authenticated-orcid":false,"given":"Juan","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Shuang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Dunaief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2020.03.019_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.019_bib2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.019_bib3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.bbagen.2009.07.026","article-title":"Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential","volume":"1790","author":"Shay","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.oret.2020.03.019_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.preteyeres.2017.03.002","article-title":"The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD","volume":"60","author":"Datta","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2020.03.019_bib5","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bbamcr.2012.04.002","article-title":"Cap-independent Nrf2 translation is part of a lipoic acid-stimulated detoxification stress response","volume":"1823","author":"Shay","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.oret.2020.03.019_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2174\/0929867043365387","article-title":"Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress","volume":"11","author":"Smith","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.oret.2020.03.019_bib7","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archopht.121.8.1099","article-title":"Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch\u2019s membrane","volume":"121","author":"Hahn","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.019_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1352458509359722","article-title":"Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters","volume":"16","author":"Yadav","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.oret.2020.03.019_bib9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/BF00400603","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)","volume":"38","author":"Ziegler","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.oret.2020.03.019_bib10","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2020.03.019_bib11","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1212\/NXI.0000000000000374","article-title":"Lipoic acid in secondary progressive MS: a randomized controlled pilot trial","volume":"4","author":"Spain","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.oret.2020.03.019_bib12","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/OPTH.S115900","article-title":"Tolerability in the elderly population of high-dose alpha lipoic acid: a potential antioxidant therapy for the eye","volume":"10","author":"Sarezky","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.019_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065389","article-title":"Alpha-lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction","volume":"8","author":"Inman","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.oret.2020.03.019_bib14","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1167\/iovs.14-15025","article-title":"Systemic administration of the antioxidant\/iron chelator alpha-lipoic acid protects against light-induced photoreceptor degeneration in the mouse retina","volume":"55","author":"Zhao","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2020.03.019_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jneuroim.2003.11.021","article-title":"Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis","volume":"148","author":"Morini","year":"2004","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.oret.2020.03.019_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neurobiolaging.2005.12.014","article-title":"Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice","volume":"28","author":"Quinn","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.oret.2020.03.019_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1570-0232(02)00010-7","article-title":"High-performance liquid chromatographic assay for alpha-lipoic acid and five of its metabolites in human plasma and urine","volume":"769","author":"Teichert","year":"2002","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.oret.2020.03.019_bib18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1177\/0091270003258654","article-title":"Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers","volume":"43","author":"Teichert","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.oret.2020.03.019_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of Atrophy report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.019_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A\u00a0computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.019_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/jamaophthalmol.2013.572","article-title":"Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of Age-Related Eye Disease Study report no. 26","volume":"131","author":"Feuer","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.019_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jclinepi.2012.09.002","article-title":"Sample size calculations for pilot randomized trials: a confidence interval approach","volume":"66","author":"Cocks","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.oret.2020.03.019_bib23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2307\/2531734","article-title":"Models for longitudinal data: a generalized estimating equation approach","volume":"44","author":"Zeger","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.oret.2020.03.019_bib24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A\u00a0randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.019_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.oret.2017.08.018","article-title":"Design characteristics of geographic atrophy treatment trials: systematic review of registered trials in ClinicalTrials.gov","volume":"2","author":"Cheng","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2020.03.019_bib26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.019_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.019_bib28","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.ajo.2015.08.024","article-title":"Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration: the GATE Study","volume":"160","author":"Jaffe","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.oret.2020.03.019_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.oret.2017.08.015","article-title":"Treatment of geographic atrophy with intravitreal sirolimus: the Age-Related Eye Disease Study 2 Ancillary Study","volume":"2","author":"Gensler","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2020.03.019_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.oret.2019.11.011","article-title":"Safety and efficacy of subretinally administered palucorcel for geographic atrophy of age-related macular degeneration: phase 2b study","volume":"4","author":"Heier","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2020.03.019_bib31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ophtha.2019.12.009","article-title":"Natural history of geographic atrophy secondary to age-related macular degeneration: results from the prospective Proxima A and B clinical trials","volume":"127","author":"Holekamp","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.019_bib32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.oret.2018.03.004","article-title":"Geographic atrophy trials: turning the ship around may not be that easy","volume":"2","author":"Guymer","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2020.03.019_bib33","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ophtha.2018.02.027","article-title":"Preventing the growth of geographic atrophy: an important therapeutic target in age-related macular degeneration","volume":"125","author":"Rosenfeld","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2020.03.019_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jamaophthalmol.2013.5799","article-title":"Geographic atrophy: a histopathological assessment","volume":"132","author":"Bird","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2020.03.019_bib36","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.ophtha.2014.06.034","article-title":"Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration","volume":"121","author":"Wu","year":"2014","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020301214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653020301214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:28:17Z","timestamp":1762853297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653020301214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2468653020301214"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2020.03.019","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2020.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}